Submission of newspaper publication of unaudited financial results for June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd has submitted to BSE copies of the newspaper publication of its unaudited standalone financial results for the quarter ended June 30, 2025, as required under SEBI LODR Regulation 47. The results were published on August 15, 2025 in The Business Standard (English) and The Nirbhaya Vaartha (Telugu) Hyderabad editions. The signed letter was submitted by Whole-time Director Venkateshwarlu Pulluru on August 16, 2025. This is a routine compliance filing confirming that the company's quarterly results have been publicly disclosed through newspapers as mandated by SEBI rules. The detailed results were already approved by the Board and filed with stock exchanges under Regulation 33.
This is a procedural compliance disclosure and does not represent new financial information or a material business event. No direct impact on shareholders or stock price is expected from this filing alone.